​

ArriVent BioPharma (AVBP) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

AVBP Stock Forecast

ArriVent BioPharma (AVBP) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $33.00, with a high of $33.00 and a low of $33.00. This represents a 63.04% increase from the last price of $20.24.

$15 $19 $23 $27 $31 $35 High: $33 Avg: $33 Low: $33 Last Closed Price: $20.24

AVBP Stock Rating

ArriVent BioPharma stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

AVBP Price Target Upside V Benchmarks

TypeNameUpside
StockArriVent BioPharma63.04%
SectorHealthcare Stocks 19.91%
IndustryBiotech Stocks 55.52%

Price Target Trends

1M3M12M
# Anlaysts114
Avg Price Target$33.00$33.00$33.75
Last Closing Price$20.24$20.24$20.24
Upside/Downside63.04%63.04%66.75%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 2517---8
Jun, 2517---8
May, 2516---7
Apr, 2516---7
Mar, 2514---5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 10, 2025Corinne JohnsonGoldman Sachs$33.00$22.0349.80%63.04%
Sep 10, 2024Yigal NochomovitzCitigroup$36.00$27.9328.89%77.87%
Sep 10, 2024Robert BurnsH.C. Wainwright$36.00$28.0428.39%77.87%
Aug 16, 2024Robert BurnsH.C. Wainwright$30.00$23.6227.01%48.22%
Jul 22, 2024Jeff JonesOppenheimer$35.00$18.7786.47%72.92%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 24, 2025OppenheimerOutperformOutperformhold
Sep 10, 2024CitigroupBuyBuyhold
Sep 10, 2024OppenheimerOutperformOutperformhold
Sep 10, 2024H.C. WainwrightBuyBuyhold
Aug 16, 2024H.C. WainwrightBuyBuyhold
Jul 22, 2024OppenheimerOutperforminitialise

Financial Forecast

EPS Forecast

$-9 $-8 $-7 $-6 $-5 $-4 $-3 $-2 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-2.07----
Avg Forecast$-8.54$-2.70$-3.25$-3.70$-2.41
High Forecast$-8.54$-2.63$-2.27$-2.13$-2.41
Low Forecast$-8.54$-2.86$-3.82$-4.57$-2.41
Surprise %-75.76%----

Revenue Forecast

$-5M $12M $29M $46M $63M $80M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported-----
Avg Forecast$-1.67M$3.00M$5.50M$4.85M$76.63M
High Forecast$-1.67M$3.00M$5.50M$4.85M$78.89M
Low Forecast$-1.67M$3.00M$5.50M$4.85M$74.37M
Surprise %-----

Net Income Forecast

$-300M $-250M $-200M $-150M $-100M $-50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-69.33M----
Avg Forecast$-272.93M$-87.65M$-106.52M$-114.65M$-77.02M
High Forecast$-272.93M$-84.03M$-72.62M$-67.91M$-77.02M
Low Forecast$-272.93M$-91.27M$-122.10M$-146.04M$-77.02M
Surprise %-74.60%----

AVBP Forecast FAQ

Is ArriVent BioPharma stock a buy?

ArriVent BioPharma stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that ArriVent BioPharma is a favorable investment for most analysts.

What is ArriVent BioPharma's price target?

ArriVent BioPharma's price target, set by 5 Wall Street analysts, averages $33 over the next 12 months. The price target range spans from $33 at the low end to $33 at the high end, suggesting a potential 63.04% change from the previous closing price of $20.24.

How does ArriVent BioPharma stock forecast compare to its benchmarks?

ArriVent BioPharma's stock forecast shows a 63.04% upside, outperforming the average forecast for the healthcare stocks sector (19.91%) and outperforming the biotech stocks industry (55.52%).

What is the breakdown of analyst ratings for ArriVent BioPharma over the past three months?

  • July 2025: 12.50% Strong Buy, 87.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2025: 12.50% Strong Buy, 87.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is ArriVent BioPharma’s EPS forecast?

ArriVent BioPharma's average annual EPS forecast for its fiscal year ending in December 2024 is $-2.7, marking a 30.43% increase from the reported $-2.07 in 2023. Estimates for the following years are $-3.25 in 2025, $-3.7 in 2026, and $-2.41 in 2027.

What is ArriVent BioPharma’s revenue forecast?

ArriVent BioPharma's average annual revenue forecast for its fiscal year ending in December 2024 is $3M, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $5.5M, followed by $4.85M for 2026, and $76.63M for 2027.

What is ArriVent BioPharma’s net income forecast?

ArriVent BioPharma's net income forecast for the fiscal year ending in December 2024 stands at $-87.647M, representing an 26.42% increase from the reported $-69.333M in 2023. Projections indicate $-107M in 2025, $-115M in 2026, and $-77.016M in 2027.